Compare Stocks: NERV, SLDB, CYRX, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.53 +6.3%	$5.01	$1.50 ▼ $5.88	$726.25M	0.78	1.73 million shs	1.95 million shs
CYRX CryoPort	$15.49 +2.7%	$15.46	$6.69 ▼ $16.89	$760.57M	1.89	633,868 shs	424,487 shs
NERV Minerva Neurosciences	$3.97 -0.3%	$4.58	$1.76 ▼ $12.46	$185.42M	-0.1	172,601 shs	83,773 shs
SLDB Solid Biosciences	$8.02 -0.5%	$8.44	$3.79 ▼ $11.45	$793.50M	2.41	1.20 million shs	905,525 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-0.57%	-6.47%	+17.91%	+239.87%
CYRX CryoPort	0.00%	-1.82%	-2.58%	+45.80%	+107.57%
NERV Minerva Neurosciences	0.00%	-1.49%	-21.96%	-34.43%	+106.75%
SLDB Solid Biosciences	0.00%	+2.94%	-25.65%	+13.04%	+18.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.53 +6.3%	$5.01	$1.50 ▼ $5.88	$726.25M	0.78	1.73 million shs	1.95 million shs
CYRX CryoPort	$15.49 +2.7%	$15.46	$6.69 ▼ $16.89	$760.57M	1.89	633,868 shs	424,487 shs
NERV Minerva Neurosciences	$3.97 -0.3%	$4.58	$1.76 ▼ $12.46	$185.42M	-0.1	172,601 shs	83,773 shs
SLDB Solid Biosciences	$8.02 -0.5%	$8.44	$3.79 ▼ $11.45	$793.50M	2.41	1.20 million shs	905,525 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-0.57%	-6.47%	+17.91%	+239.87%
CYRX CryoPort	0.00%	-1.82%	-2.58%	+45.80%	+107.57%
NERV Minerva Neurosciences	0.00%	-1.49%	-21.96%	-34.43%	+106.75%
SLDB Solid Biosciences	0.00%	+2.94%	-25.65%	+13.04%	+18.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	107.96% Upside
CYRX CryoPort	2.78	Moderate Buy	$16.38	5.71% Upside
NERV Minerva Neurosciences	2.00	Hold	$10.50	164.48% Upside
SLDB Solid Biosciences	2.91	Moderate Buy	$17.11	113.36% Upside

Current Analyst Ratings Breakdown

Latest NERV, SLDB, CYRX, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2026	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	CYRX CryoPort	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.50
6/8/2026	CYRX CryoPort	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$13.00
6/3/2026	CYRX CryoPort	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
6/3/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
6/2/2026	ACRS Aclaris Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$13.00
6/1/2026	ACRS Aclaris Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2026	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$15.00 ➝ $17.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	98.64	N/A	N/A	$0.85 per share	6.51
CYRX CryoPort	$176.18M	4.43	N/A	N/A	$9.19 per share	1.69
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.56	N/A	N/A	N/A	-832.58%	-55.89%	-38.49%	8/6/2026 (Estimated)
CYRX CryoPort	$78.30M	$1.35	11.47	N/A	N/A	41.57%	-7.92%	-4.79%	8/6/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$29.16	N/A	0.82	N/A	N/A	N/A	-32.63%	8/13/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.95	N/A	N/A	N/A	N/A	-73.42%	-61.13%	8/11/2026 (Estimated)

Latest NERV, SLDB, CYRX, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	SLDB Solid Biosciences	-$0.43	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	N/A	N/A	N/A	$1.38 million	N/A
8/6/2026	Q2 2026	CYRX CryoPort	-$0.20	N/A	N/A	N/A	$48.21 million	N/A
5/12/2026	Q1 2026	SLDB Solid Biosciences	-$0.40	-$0.52	-$0.12	-$0.52	N/A	N/A
5/7/2026	Q1 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.32 million	$2.00 million
5/5/2026	Q1 2026	NERV Minerva Neurosciences	-$0.13	-$0.17	-$0.04	-$2.86	N/A	N/A
5/4/2026	Q1 2026	CYRX CryoPort	-$0.20	-$0.23	-$0.03	-$0.25	$44.86 million	$47.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	4.03	4.03
CYRX CryoPort	N/A	2.09	2.00
NERV Minerva Neurosciences	N/A	17.65	17.65
SLDB Solid Biosciences	N/A	13.10	13.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CYRX CryoPort	92.90%
NERV Minerva Neurosciences	34.56%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CYRX CryoPort	9.50%
NERV Minerva Neurosciences	1.70%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.66 million	132.96 million	Optionable
CYRX CryoPort	1,186	50.40 million	45.61 million	Optionable
NERV Minerva Neurosciences	9	46.59 million	45.80 million	Not Optionable
SLDB Solid Biosciences	100	98.45 million	95.83 million	Optionable

NERV, SLDB, CYRX, and ACRS Headlines

Recent News About These Companies

Janus Henderson Group PLC Acquires Shares of 4,010,695 Solid Biosciences Inc. $SLDB

August 3 at 5:19 AM | marketbeat.com

Stempoint Capital LP Purchases New Position in Solid Biosciences Inc. $SLDB

July 30, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Holdings Boosted by Redmile Group LLC

July 29, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Shares Purchased by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 26, 2026 | americanbankingnews.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading Down 9% - Here's What Happened

July 10, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

May 24, 2026 | theglobeandmail.com

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

May 20, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

May 14, 2026 | theglobeandmail.com

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026 | globenewswire.com

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

May 7, 2026 | globenewswire.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026 | globenewswire.com

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

April 30, 2026 | globenewswire.com

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

April 28, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, SLDB, CYRX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.53 +0.33 (+6.35%)

Closing price 04:00 PM Eastern

Extended Trading

$5.48 -0.04 (-0.81%)

As of 07:45 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CryoPort NASDAQ:CYRX

$15.49 +0.40 (+2.65%)

Closing price 04:00 PM Eastern

Extended Trading

$15.48 -0.01 (-0.03%)

As of 07:34 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Minerva Neurosciences NASDAQ:NERV

$3.97 -0.01 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 -0.01 (-0.13%)

As of 04:19 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$8.02 -0.04 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$8.02 +0.01 (+0.06%)

As of 07:34 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, SLDB, CYRX, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, SLDB, CYRX, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, SLDB, CYRX, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, SLDB, CYRX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

CryoPort NASDAQ:CYRX

Minerva Neurosciences NASDAQ:NERV

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, SLDB, CYRX, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, SLDB, CYRX, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, SLDB, CYRX, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, SLDB, CYRX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

CryoPort NASDAQ:CYRX

Minerva Neurosciences NASDAQ:NERV

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools